Sexual dimorphism of the immune system predicts clinical outcomes in glioblastoma immunotherapy: A systematic review and meta-analysis

Resource type: Publication Publication
  • Authors
    Shireman J.M.; Ammanuel S.; Eickhoff J.C.; Dey M.
  • Type
    Original Research
  • Journal
    Neuro-Oncology Advances
  • Publication Date
    2022
  • Abstract

    Biological differences based on sex have been documented throughout the scientific literature. Glioblastoma (GBM), the most common primary malignant brain tumor in adults, has a male sex incidence bias, however, no clinical trial data examining differential effects of treatment between sexes currently exists.

Access Publication